A non-aggressive Clostridium difficile strain significantly reduced the risk of Clostridium difficile infection (CDI) recurrence in a small study published in the Journal of the American Medical Association.
In the first study to assess the use of the relaxation response for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), a nine-week training program including use of the relaxation response had a significant impact on the clinical symptoms of these disorders.
A medication indicated to treat type 2 diabetes could be a future therapeutic option for non-alcoholic steatohepatitis (NASH) after a study met its primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.
Movantik (naloxegol) is now available for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
A study in the journal Microbiome has found that changes to a patient's microbiome that are characterized as healthy after fecal microbiota transplantation (FMT) may be sustained for up to 21 weeks post-transplant.
Nocturnal gastroesophageal reflux disease (GERD) appears to be a risk factor for non-infectious rhinitis (NIR), according to a new study.
A study found visceral abdominal obesity, not general obesity, is a significant independent risk factor of IBS, especially IBS-D.
Selective serotonin reuptake inhibitor (SSRI) use is associated with increased risk of upper gastrointestinal bleeding.